BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu R, Wang G, Zhang C, Bai D. A prognostic model for hepatocellular carcinoma based on apoptosis-related genes. World J Surg Oncol 2021;19:70. [PMID: 33712023 DOI: 10.1186/s12957-021-02175-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021;27:8069-80. [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069] [Reference Citation Analysis]
3 Ruiz E, Pineau P, Flores C, Fernández R, Cano L, Cerapio JP, Casavilca-Zambrano S, Berrospi F, Chávez I, Roche B, Bertani S. A preoperative nomogram for predicting long-term survival after resection of large hepatocellular carcinoma (>10 cm). HPB (Oxford) 2021:S1365-182X(21)00177-5. [PMID: 34226129 DOI: 10.1016/j.hpb.2021.06.006] [Reference Citation Analysis]
4 Lu SD, Li L, Liang XM, Chen W, Chen FL, Fan LL, Ahir BK, Zhang WG, Zhong JH. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Rev Gastroenterol Hepatol 2019;13:1077-88. [PMID: 31648568 DOI: 10.1080/17474124.2019.1684898] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
6 Zhao H, Xie Z, Tang G, Wei S, Chen G. Knockdown of terminal differentiation induced ncRNA (TINCR) suppresses proliferation and invasion in hepatocellular carcinoma by targeting the miR-218-5p/DEAD-box helicase 5 (DDX5) axis. J Cell Physiol 2020;235:6990-7002. [PMID: 31994189 DOI: 10.1002/jcp.29595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang H, Sun L, Guan A, Yin H, Liu M, Mao X, Xu H, Zhao H, Lu X, Sang X, Zhong S, Chen Q, Mao Y. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70:667-677. [PMID: 32876735 DOI: 10.1007/s00262-020-02711-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Kumazaki M, Shimomura I, Kiyono T, Ochiya T, Yamamoto Y. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells. Biochemical and Biophysical Research Communications 2020;525:483-90. [DOI: 10.1016/j.bbrc.2020.02.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
10 Chen ZY, Guo ZX, Lu LH, Mei J, Lin WP, Li SH, Wei W, Guo RP. The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma. Cancer Med 2021;10:5466-74. [PMID: 34212527 DOI: 10.1002/cam4.4102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Yang F, Zhang Y, Ren H, Wang J, Shang L, Liu Y, Zhu W, Shi X. Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis. J Exp Clin Cancer Res 2019;38:489. [PMID: 31831037 DOI: 10.1186/s13046-019-1480-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
12 Matsuda M, Ichikawa S, Matsuda M, Amemiya H, Ichikawa D, Onishi H, Motosugi U. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement as a risk factor for late recurrence (>1 year) of hepatocellular carcinoma after surgery. Clin Radiol 2019;74:975.e1-9. [PMID: 31540704 DOI: 10.1016/j.crad.2019.08.002] [Reference Citation Analysis]
13 Sun LY, Ouyang Q, Cen WJ, Wang F, Tang WT, Shao JY. A Model Based on Artificial Intelligence Algorithm for Monitoring Recurrence of HCC after Hepatectomy. Am Surg 2021;:31348211063549. [PMID: 34894786 DOI: 10.1177/00031348211063549] [Reference Citation Analysis]
14 Li J, Yang X, Huang L, Zhu X, Qiu M, Yan J, Yan Y, Wei S. Treatment Strategy for Post-hepatectomy Recurrent Hepatocellular Carcinoma Within the Milan Criteria: Repeat Resection, Local Ablative Therapy or Transarterial Chemoembolization? Indian J Surg. [DOI: 10.1007/s12262-022-03343-1] [Reference Citation Analysis]
15 Yoon JH, Lee WJ, Kim SM, Kim KT, Cho SB, Kim HJ, Ko YS, Kook HY, Jun CH, Choi SK, Kim BS, Cho SY, You HS, Lee Y, Son S. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Sci Rep 2021;11:12984. [PMID: 34155324 DOI: 10.1038/s41598-021-92503-6] [Reference Citation Analysis]
16 Chen Y, Wu T, Zhu Z, Huang H, Zhang L, Goel A, Yang M, Wang X. An integrated workflow for biomarker development using microRNAs in extracellular vesicles for cancer precision medicine. Semin Cancer Biol 2021:S1044-579X(21)00061-4. [PMID: 33766650 DOI: 10.1016/j.semcancer.2021.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li J, Huang L, Liu C, Qiu M, Yan J, Yan Y, Wei S. Risk factors and clinical outcomes of extrahepatic recurrence in patients with post-hepatectomy recurrent hepatocellular carcinoma. ANZ J Surg 2021;91:1174-9. [PMID: 33724680 DOI: 10.1111/ans.16737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol 2021;14:699-713. [PMID: 33774785 DOI: 10.1007/s12328-021-01394-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zheng J, Cai J, Tao L, Kirih MA, Shen Z, Xu J, Liang X. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. International Journal of Surgery 2020;83:196-204. [DOI: 10.1016/j.ijsu.2020.09.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Xu W, Liu F, Shen X, Li R. Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. J Hepatocell Carcinoma 2020;7:233-56. [PMID: 33154956 DOI: 10.2147/JHC.S271498] [Reference Citation Analysis]
21 Tan HL, Goh BKP. Management of recurrent hepatocellular carcinoma after resection. Hepatobiliary Surg Nutr 2020;9:780-3. [PMID: 33299834 DOI: 10.21037/hbsn.2020.03.07] [Reference Citation Analysis]
22 Erridge S, Sodergren MH. The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction.Hepatobiliary Surg Nutr. 2019;8:298-300. [PMID: 31245419 DOI: 10.21037/hbsn.2019.01.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Peng W, Li C, Zhang X, Wen T, Chen Z. The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis. World J Surg Oncol 2021;19:46. [PMID: 33573630 DOI: 10.1186/s12957-021-02160-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Li Z, Liang L, Duan W, Zhou C, Yang JJ. Non-linear relationship of gamma-glutamyl transpeptidase to lymphocyte count ratio with the recurrence of hepatocellular carcinoma with staging I-II: a retrospective cohort study. Infect Agent Cancer 2022;17:16. [PMID: 35395799 DOI: 10.1186/s13027-022-00428-0] [Reference Citation Analysis]
25 Hu X, Jiao F, Zhang L, Jiang Y. Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway. Front Pharmacol 2021;12:654986. [PMID: 33995073 DOI: 10.3389/fphar.2021.654986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yao SY, Liang B, Chen YY, Tang YT, Dong XF, Liu TQ. Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study. World J Clin Cases 2021; 9(27): 8020-8026 [PMID: 34621858 DOI: 10.12998/wjcc.v9.i27.8020] [Reference Citation Analysis]
27 Li C, Peng W, Zhang XY, Wen TF, Chen LP. The preoperative platelet to albumin ratio predicts the prognosis of hepatocellular carcinoma patients without portal hypertension after liver resection. Medicine (Baltimore) 2019;98:e17920. [PMID: 31702672 DOI: 10.1097/MD.0000000000017920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Alexandrescu ST, Croitoru AE, Grigorie RT, Tomescu DR, Droc G, Grasu MC, Popescu I. Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy. Hepatobiliary Pancreat Dis Int 2021;20:28-33. [PMID: 32917528 DOI: 10.1016/j.hbpd.2020.08.008] [Reference Citation Analysis]
29 Peng W, Yao M, Zou K, Li C, Wen T, Sun X. Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study. BMC Surg 2021;21:338. [PMID: 34493254 DOI: 10.1186/s12893-021-01334-9] [Reference Citation Analysis]
30 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
31 Huang H, Lu X, Yang H, Xu Y, Sang X, Zhao H. Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review. Ann Transl Med 2019;7:795. [PMID: 32042811 DOI: 10.21037/atm.2019.11.99] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Wu Z, Guo W, Chen S, Zhuang W. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy. Invest New Drugs 2021;39:394-9. [PMID: 33006020 DOI: 10.1007/s10637-020-01009-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Xu M, Ma T, Shi S, Xing J, Xi Y. Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma. Life (Basel) 2021;11:1312. [PMID: 34947843 DOI: 10.3390/life11121312] [Reference Citation Analysis]
34 Tanaka K, Takahashi Y, Wakabayashi T. An international expert consensus of management of recurrent hepatocellular carcinoma: a viewpoint. Hepatobiliary Surg Nutr 2020;9:394-6. [PMID: 32509840 DOI: 10.21037/hbsn.2019.10.23] [Reference Citation Analysis]